Stericycle, Inc. (NASDAQ:SRCL) tinted gains of +1.67% (+1.12 points) to US$68.35. The volume of 1.14 Million shares climbed down over an trading activity of 789.93 Million shares. EPS ratio determined by looking at last 12 month figures is -1.62. Over the same time span, the stock marked US$83.25 as its best level and the lowest price reached was US$56.64. The corporation has a market cap of US$5.84 Billion.
Stericycle, Inc. (NASDAQ:SRCL)’s earnings per share has been growing at a -19.2 percent rate over the past 5 year when average revenue increase was noted as 13.4 percent. The return on equity ratio or ROE stands at -0.3 percent while most common profitability ratio return on investment (ROI) was 0.2 percent. The company’s institutional ownership is monitored at 0 percent. The company’s net profit margin has achieved the current level of -0.3 percent and possesses 40.5 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 3 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 6 think it is Hold. Recently, analysts have updated the overall rating to 2.27. 2 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Leidos Holdings, Inc. (NYSE:LDOS) is worth US$9.49 Billion and has recently risen 1.66% to US$62.46. The latest exchange of 0.69 Million shares is below its average trading activity of 1.01 Million shares. The day began at US$61.51 but the price moved to US$61.5 at one point during the trading and finally capitulating to a session high of US$62.54. The stock tapped a 52-week high of US$70.11 while the mean 12-month price target for the shares is US$76.
Currently, the stock carries a price to earnings ratio of 34.15, a price to book ratio of 2.77, and a price to sales ratio of 0.95. For the past 5 years, the company’s revenue has grown 9.5%, while the company’s earnings per share has grown -16%. With an institutional ownership near 76.1%, it carries an earnings per share ratio of 1.83.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 4 brokerage firms polled by Factset Research. At present, 2 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 5 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.82.